Psyence Biomedical Ltd. (PBM)
NasdaqCM: PBM
· Real-Time Price · USD
3.35
-0.05 (-1.47%)
At close: Aug 12, 2026, 2:35 PM
Psyence Biomedical Ltd. (PBM) Stock Price, Analysis & Data
-1.47% (1D)
| Bid | 2.45 |
| Market Cap | 12.78M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -6.94M |
| Beta | 1.67 |
| EPS (ttm) | -12.56 |
| PE Ratio (ttm) | n/a |
| Forward PE | n/a |
| P/B (ttm) | 0.45 |
| P/S (ttm) | n/a |
| Earnings Date | n/a |
| Ask | 4.31 |
| Volume | 20,564 |
| Avg. Volume (20D) | 85,496 |
| Open | 3.38 |
| Previous Close | 3.40 |
| Day's Range | 3.31 - 3.42 |
| 52-Week Range | 1.92 - 216.41 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About PBM
Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting. The company is based in Toronto, Canada. Psyence Biomedical Ltd. is a subsidiary of Psyence Group Inc....
Industry Biotechnology
Sector Healthcare
IPO Date Dec 10, 2021
Employees 12
Stock Exchange NasdaqCM
Ticker Symbol PBM
Website https://psyencebiomed.com
Financial Performance
In 2026, Psyence Biomedical's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -6.94M, a decrease of -785.56%.
Financial Statements
Page 1 of 2